Therapy News and Research

RSS

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

Yoga improves physical, mental wellbeing of people living with common forms of arthritis

A randomized trial of people with two common forms of arthritis has found that yoga can be safe and effective for people with arthritis. Johns Hopkins researchers report that 8 weeks of yoga classes improved the physical and mental wellbeing of people with two common forms of arthritis, knee osteoarthritis and rheumatoid arthritis.

16 Sep 2015

Hitachi receives FDA 510(k) clearance to deliver new PROBEAT-V system to Rochester-based Mayo Clinic

Hitachi, Ltd. has announced it has received FDA 510(k) clearance for commercial supply of the new PROBEAT-V system, which it designed and developed for Mayo Clinic in Rochester, MN. Treatments began in late June and the first patient treatment was completed in August 2015.

16 Sep 2015

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer's dementia.

16 Sep 2015

Florida Institute finalizes funding agreement with MYOLYN

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with MYOLYN, a Gainesville-based company with technology licensed from the University of Florida.

15 Sep 2015

Massage therapy improves health related quality of life for cancer patients

Recent studies show massage therapy can reduce pain, stress, nausea, depression, distress, anxiety and fatigue, while improving health related quality of life for cancer patients.

15 Sep 2015

Roflumilast drug could inhibit growth of brain tumor in children

Current drugs may stop working against the most common type of brain tumor in children, medulloblastoma, but the tumor could be targeted in a new way, according to Stanford University scientists.

15 Sep 2015

Population health study examines real-world osteoporosis treatment patterns

A statewide study has found that from 2005 to 2012, fewer than a quarter of men and women with documentation of osteoporosis or fragility fracture, conditions for which national guidelines would recommend treatment for osteoporosis, actually received that treatment.

15 Sep 2015

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

15 Sep 2015

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.

15 Sep 2015

Findings suggest link between cancer drug resistance and reactive oxygen species found in mitochondria

Increased levels of certain chemically reactive, oxygen-containing molecules in the body can cause patients to become resistant to cancer drugs such as chemotherapy, according to researchers at Georgia State University.

15 Sep 2015

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials.

15 Sep 2015

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.

15 Sep 2015

BfArM approves Greenovation’s moss-aGal phase I clinical trial for Fabry disease

Greenovation Biotech GmbH announced today that it has received approval to begin a phase I clinical trial in Europe for its first drug candidate moss-aGal (agalsidase) from Germany's regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM).

15 Sep 2015

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Sep 2015

Better treatment could be on the horizon for Myasthenia Gravis

Myasthenia Gravis (MG) is a debilitating and potentially deadly disease that can afflict anyone, characterized by severe muscle weakness, affecting control of facial expressions, arm and leg movements, chewing, swallowing, coughing and breathing. There is no cure, only treatment.

14 Sep 2015

Novel long non-coding RNA has potential to stymie growth of tumor cells in colon cancer

Genetics researchers from Case Western Reserve School of Medicine have identified a novel long non-coding RNA (lncRNA), dubbed DACOR1, that has the potential to stymie the growth of tumor cells in the second-most deadly form of cancer in the U.S. — colorectal cancer.

14 Sep 2015

UNC scientists create smarter immune cells to treat Parkinson's disease

As a potential treatment for Parkinson's disease, scientists at the University of North Carolina at Chapel Hill have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves.

14 Sep 2015

Two St. Louis institutions collaborate to create Center for Clinical Pharmacology

St. Louis College of Pharmacy and Washington University School of Medicine in St. Louis are joining forces to find better, safer and more effective ways to use prescription medications to improve health. Researchers from the two institutions are collaborating to create the Center for Clinical Pharmacology.

14 Sep 2015

Valtech receives CE Mark approval for Cardioband Mitral Reconstruction System

Valtech Cardio, Ltd.,, an innovator in the development of devices for mitral and tricuspid valve repair and replacement, announced today it has received Conformite Europeenne (CE) Marking for its Cardioband Mitral Reconstruction System (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

14 Sep 2015

Therapy News and Research

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

Yoga improves physical, mental wellbeing of people living with common forms of arthritis

Hitachi receives FDA 510(k) clearance to deliver new PROBEAT-V system to Rochester-based Mayo Clinic

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Florida Institute finalizes funding agreement with MYOLYN

Massage therapy improves health related quality of life for cancer patients

Roflumilast drug could inhibit growth of brain tumor in children

Population health study examines real-world osteoporosis treatment patterns

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Findings suggest link between cancer drug resistance and reactive oxygen species found in mitochondria

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

BfArM approves Greenovation’s moss-aGal phase I clinical trial for Fabry disease

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Better treatment could be on the horizon for Myasthenia Gravis

Novel long non-coding RNA has potential to stymie growth of tumor cells in colon cancer

UNC scientists create smarter immune cells to treat Parkinson's disease

Two St. Louis institutions collaborate to create Center for Clinical Pharmacology

Valtech receives CE Mark approval for Cardioband Mitral Reconstruction System

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News